Диссертация (1139510), страница 50
Текст из файла (страница 50)
JournalofPsychopharmacology. 2008;22:343–396.53. Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology ofmajor depressive episodes: results from the International Consortium of PsychiatricEpidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3–21.54. Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., and Thomson, J. A. Jr.(2015). Is serotonin an upper or a downer? The evolution of the serotonergicsystem and its role in depression and the antidepressant response. Neurosci.Biobehav.
Rev. 51, 164–188.55. Angst J, Dobler-Mikola A. Do the diagnostic criteria determine the sex ratioin depression? J Affect Disord. 1984;7:189-198.56. Angst, J., & Clayton, P. (1986). Premorbid personality of depressive, bipolar,and schizophrenic patients with special reference to suicidal issues.Comprehensive psychiatry, 27(6), 511–32.57. Arias B, Catalán R, Gastó C, Gutiérrez B, Fañanás L.
Evidence for acombined genetic effect of the 5-HT(1A) receptor and serotonin transporter genesin the clinical outcome of major depressive patients treated with citalopram. JPsychopharmacol. 2005 Mar;19(2):166-72.58. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J. World272Federation of Societies of Biological Psychiatry (WFSBP) guidelines forbiological treatment of unipolar depressive disorders, part 1: update 2013 on theacute and continuation treatment of unipolar depressive disorders. World J BiolPsychiatry.
2013 Jul;14(5):334-85.59. Bauer M, Pretorius HW , Constant EL , Earley WR , Szamosi J , Brecher M.2009b . Extended-release quetiapine as adjunct to an antidepressant in patientswith major depressive disorder: results of a randomized, placebo-controlled,double-blind study . J Clin Psychiatry 70 : 540 – 549 .60. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies ofBiological Psychiatry (WFSBP) Guidelines for biological treatment of unipolardepressive disorders, Part 1: Acute and continuation treatment of major depressivedisorder.
The World Journal of Biological Psychiatry. 2002;3:5–43.61.Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies ofBiological Psychiatry (WFSBP) guidelines for biological treatment of unipolardepressive disorders, Part 2: Maintenance treatment of major depressive disorderand treatment of chronic depressive disorders and subthreshold depressions. TheWorld Journal of Biological Psychiatry.
2002;3:69–86.62. Baumann P . 1996 . Pharmacokinetic-pharmacodynamic relationship of theselective serotonin reuptake inhibitors . Clin Pharmacokinet 31 : 444 – 46963. Baumeister H, Parker G: Meta-review of depressive subtyping models. JAffect Disord 2012, 139(2):126-140.64. Bayes AJ, Parker GB. Comparison of guidelines for the treatment ofunipolar depression: a focus on pharmacotherapy and neurostimulation.
ActaPsychiatr Scand. 2018 Jun;137(6):459-471.65. Beard C, Millner AJ et al. Network Analysis of Depression and AnxietySymptom Relations in a Psychiatric Sampl. Psychol Med. 2016 December ;46(16): 3359–3369.66. Benedetti F, Barbini B, Bernasconi A. et al. Lithium overcomes the influenceof 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation.J Clin Psychopharmacol.
2008.67. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuadeRD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazoleaugmentation in major depressive disorder: a double-blind, placebo-controlledstudy in patients with inadequate response to antidepressants. CNS Spectr. 2009Apr;14(4):197-206.68. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, CoreyLisle PK, Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in273major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry. 2007 Jun;68(6):843-53.69. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A Review Molecular geneticsof CYP2D6: clinical relevance with focus on psychotropic drugs.
Br J ClinPharmacol. 2002 Feb; 53(2):111-22.70. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, et al.Mirtazapine and paroxetine in major depression: a comparison of monotherapyversus their combination from treatment initiation. Eur Neuropsychopharmacol.2009; 19(7): 457-465. doi: http:// dx.doi.org/10.1016/j.euroneuro.2009.01.01571. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R.Combination of antidepressant medications from treatment initiation for majordepressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3): 281-28872.
Bockting CL, ten Doesschate MC, Spijker J et al. Continuation andmaintenance use of antidepressants in recurrent depression. PsychotherPsychosom 2008;77:17–26.73. Bondy B. Pathophysiology of depression. Dialogues in clinicalneuroscience. 2002; 4: 1, 7–20.;74.Bondy B. Pharmacogenomics in depression and antidepressants. DialoguesClin Neurosci. 2005 September; 7(3): 223–23075. Borsboom D, Cramer AO. Network analysis: an integrative approach to thestructure of psychopathology.
Annual Review of Clinical Psychology. 2013;9:91–121.76. Borsboom D, Epskamp S, Kievit RA, Cramer AO, Schmittmann VD.Transdiagnostic Networks Commentary on Nolen-Hoeksema and Watkins2011. Perspectives on Psychological Science. 2011;6(6):610–614.77. Borsboom D. Psychometric perspectives on diagnostic systems. J ClinPsychol 2008;64:1089-108.78. Borsboom, D. (2017). A network theory of mental disorders.
WorldPsychiatry, 16(1), 5–13.79. Boschloo L, van Borkulo CD, Borsboom D et al. A prospective study onhow symptoms in a network predict the onset of depression. PsychotherPsychosom 2016;85:183-4. 180. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians,Africans and their descendants. Pharmacogenomics. 2002;3(2):229–24381. Breitenstein B, Scheuer S, Pfister H, Uhr M, Lucae S, Holsboer F, Ising M,Brückl TM. The clinical application of ABCB1 genotyping in antidepressanttreatment: a pilot study. CNS Spectr.
2013 Jul 23:1-11. [Epub ahead of print].27482. Brodaty H, Luscombe G, Peisah C, et al. A 25-year longitudinal, comparisonstudy of the outcome of depression. Psychol Med 2001;31:1347–59.83. Bromet E, Andrade LH, Hwang I et al. Cross-national epidemiology ofDSM-IV major depressive episode. BMC Med 2011;9:9084. Bschor T, Ising M, Erbe S, et al.
Impact of citalopram on the HPA system. Astudy of the combined DEX/CRH test in 30 unipolar depressed patients. JPsychiatr Res. 2012 Jan;46(1):111-7.85. Bulloch A, Williams J, Lavorato D et al. Recurrence of major depressiveepisodes is strongly dependent on the number of previous episodes. DepressAnxiety 2014;31:72–6.86.
Burke KC, Burke JD Jr, Regier DA, et al. Age at onset of selected mentaldisorders in five community populations. Arch Gen Psychiatry. 1990;47:511-518.87.Burns RA, Lock T, Edwards DR, et al. Predictors of response toaminespecific antidepressants. J Affect Disord. 1995;35:97-106.88. Carli M, Reader TA. Regulation of central serotonin transporters by chroniclithium: An autoradiographic study. Synapse. 1997;27:83–89.89.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, CraigIW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. Candidate GenesExpression Profile Associated with Antidepressants Response in the GENDEPStudy: Differentiating between Baseline 'Predictors' and Longitudinal 'Targets'.Neuropsychopharmacology. 2013 Feb;38(3):377-85.90.
Chen S, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism:screening costs and influence on clinical outcomes in psychiatry. Clin PharmacolTher. 1996;60(5):522–53491. Cipriani A, Furukawa T A Salanti G et al. Comparative efficacy andacceptability of 21 antidepressant drugs for the acute treatment of adults withmajor depressive disorder: a systematic review and network meta-analysis.
Lancet2018; 391: 1357–66.92. Colman I, Naicker K, Zeng Y et al. Predictors of long-term prognosis ofdepression. CMAJ 2011;183:1969–76.93. Cramer AOJ, Waldorp LJ, van der Maas HLJ et al. Comorbidity: a networkperspective. Behav Brain Sci 2010;33:137-93.94. Crona L, Bradvik L. Long-term course of severe depression: late remissionand recurrence May be found in a follow-up after 38–53 years. MentIlln 2012;4:e1795. Crossley NA , Bauer M . 2007 . Acceleration and augmentation ofantidepressants with lithium for depressive disorders: two meta-analyses ofrandomized, placebo-controlled trials . J Clin Psychiatry 68 : 935 – 940 .27596. Cuthbert B., Insel T.
Toward the future of psychiatric diagnosis: the sevenpillars of RDoC. BMC Med. 2013 May 14; 11: 126–135.97. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSMto dimensional approaches that integrate neuroscience and psychopathology. WorldPsychiatry (2014) 13:28–35.98. Daly AK. Pharmacogenetics of the major polymorphic metabolizingenzymes. Fundam Clin Pharmacol. 2003;17(1):27–41.99. Damberg M. Transcription factor AP-2 and monoaminergic functions in thecentral nervous system.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
